The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

The FDA posted to its site the observations made during an inspection of an AstraZeneca (AZN) manufacturing center that was conducted from May ...

AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.

(Reuters) -AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 17,439.50 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

After hours: 7:50:59 pm GMT-5 ...